Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

Introduction & Objectives: C administration of D (8–10 consecutive courses) is usually considered as a standard 232 posters / european urology supplements 11 (2012) 191–235 treatment as first line for CRPC pts. An I administration could improve pts compliance and quality of life (QL). E is an old drug showing a synergistic action with D. This study is aimed to compare QL of C and I D and whether E added to D improved its activity, in a 2×2 factorial design. Material & Methods: CRPC pts were randomized to: C D 70 mg/m2 IV q 3 wks for 8 courses alone (arm A) or with E 280 mg/TID PO for 5 days starting 1 day prior to D (arm B), or the same treatments given with a 3-month rest period after the first 4 courses (arm C and D, respectively). The primary end points were QL (EORTC QLQ C30 and BPI) of A+B vs C+D and 1-y PFS (according to PCWG2) of A+C vs B+D. Results: 148 CRPC pts were enrolled from 11/06 to 10/10 with 130 pts evaluable at this time. The median age was 69 (range 42–81) and the median baseline PSA was 55.6 (range 0.33– 4212). The major hematological toxicities were: anemia G3 (3 pts), neutropenia G3 (4 pts) – G4 (5 pts), febrile neutropenia (5 pts). Comparing C and I, QL outcomes were not statistically different in terms of general QL items. Comparing D and DE, 1-y PFS was superimposable (10.3% and 13.2%, respectively). The 2-y overall survival was not different between I and C arms 41.5% and 50.7% respectively) and between D and DE arms (41.9% and 53.2% respectively). Conclusions: These preliminary results suggest that I treatment did not produce a QL advantage compared to C treatment, while the addition of E to D did not improve 1-y PFS of CRPC pts. Updated data with the complete sample analysis will be presented